Skip to main content

Table 2 Mortality and clinical, radiographic, and global responses at Week 6

From: Utility of CT assessment in hematology patients with invasive aspergillosis: a post-hoc analysis of phase 3 data

  cIA (N = 240) nIA (N = 155)
Mortality, n (mortality rate,a %) 54 (22.8) 31 (20.3)
Asian subpopulation n = 60 n = 37
 Mortality, n (mortality rate,a %) 14 (23.9) 8 (22.2)
Non-Asian subpopulation n = 180 n = 118
 Mortality, n (mortality rate,a %) 40 (22.5) 23 (19.8)
Clinical responses, nb (%) n = 177 n = 88
 Complete (sign/symptom resolution) 105 (59.3) 42 (47.7)
 Partial (clinical improvement) 39 (22.0) 18 (20.5)
 Stable (no discernible change) 15 (8.5) 7 (8.0)
 Failure (worsening of signs/symptoms) 7 (4.0) 4 (4.5)
Radiographic responses, nc (%) n = 177 n = 88
 Complete (> 90% radiographic improvement) 35 (19.8) 22 (25.0)
 Partial (50–90% radiographic improvement) 81 (45.8) 34 (38.6)
 Stable (< 50% radiographic improvement) 37 (20.9) 10 (11.4)
 Failure (worsening disease) 12 (6.8) 5 (5.7)
Global responses,d n (%) n = 240 n = 155
 Complete 20 (8.3) 11 (7.1)
 Partial 73 (30.4) 15 (9.7)
 Stable 39 (16.3) 8 (5.2)
 Failure 13 (5.4) 4 (2.6)
  1. aBased on Kaplan-Meier product limit estimators. bMissing data from 11 patients with cIA and 17 patients with nIA
  2. cMissing data from 12 patients with cIA and 17 patients with nIA
  3. dGlobal responses were categorized as complete (complete clinical and radiographic response), partial (clinical improvement and complete/partial radiographic response), stable (stable clinical or radiographic response), or failure (worsening disease); missing data from 95 patients with cIA and 117 patients with nIA.cIA ‘Confirmed’ invasive aspergillosis, nIA ‘Non-confirmed’ invasive aspergillosis